We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SAL:LSESpaceandPeople plc Analysis

Data as of 2026-03-16 - not real-time

£210.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

SpaceandPeople plc (SAL.L) is trading at £210, just above its 20‑day SMA of £210.25 and comfortably above the 200‑day SMA of £185.88, indicating a bullish long‑term trend. The RSI sits at a neutral 51.5, while the MACD histogram remains negative, suggesting short‑term momentum weakness despite the overall bullish bias. Volume is on a decreasing trajectory, and 30‑day volatility is elevated at 23%, which together flag a modest short‑term risk. The company’s fundamentals are compelling: revenue grew 26% year‑over‑year, gross margins are exceptionally high at 81.8%, and cash on hand exceeds debt, yielding a debt‑to‑equity of only 34%. Valuation metrics reinforce the upside narrative – the PE ratio of 8.75 is well below the industry average of 17.8, and the DCF‑derived fair value suggests a potential upside of ≈48%.
From a risk perspective, the stock’s low beta (0.26) implies limited market sensitivity, while the advertising‑services sector carries a medium cyclical risk. No dividend is paid, so dividend sustainability is not a factor. Given the strong cash generation, modest debt, and attractive valuation, the outlook leans toward a buy stance over medium to long horizons, with an emphasis on monitoring short‑term technical softness and volume trends.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish long‑term SMA alignment
  • Negative MACD histogram indicating short‑term weakness
  • Decreasing volume and elevated volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued PE relative to industry
  • Strong revenue growth and high gross margins
  • Low beta suggesting defensive characteristics

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust cash generation versus modest debt
  • Sustainable operating profitability
  • Significant upside potential from DCF fair‑value estimate

Key Metrics & Analysis

Financial Health

Revenue Growth26.20%
Profit Margin6.50%
P/E Ratio8.8
ROE14.92%
ROA3.59%
Debt/Equity34.23
P/B Ratio113.8
Op. Cash Flow£1.7M
Free Cash Flow£1.2M
Industry P/E17.8

Technical Analysis

TrendBullish
RSI51.5
Support£196.00
Resistance£239.00
MA 20£210.25
MA 50£209.26
MA 200£185.88
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value£2,392.82
Target Price£310.00
Upside/Downside47.62%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.26
Volatility22.99%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.